Agennix AG Announces Positive -2-
de clars orenda Institut & Verlag Erich E. WeißmannGarlock GmbHa3 systemsExistenzgründerhilfe Berlin Tempelhof Norbert Naujoks u. Torsten Marschner GbR> Mehr Firmen
SALT LAKE CITY, UT -- (Marketwire) -- 09/02/10 -- Spero Pain Relief Therapy, Inc. announced today the opening of the companys first of four planned pain relief clinics in Utah. The clinic is located at 348 East 600 South St. George, Utah and can be contacted by phone at (435) 656-1916. Spero has plans to expand its clinic network to include locations in Provo, Salt Lake City and Ogden using the innovative Calmarereg ; Pain Therapy Treatment pain management system from Competitive Technologies, Inc. (CTT).
Dr. Robert Chalmers, M.D., Director and Founder of Spero Pain Relief Therapy, said, "After treating a number of my patients suffering from chronic pain with CTTs Calmare Pain Therapy medical device with extraordinary results, I realized that introducing this non-narcotic alternative therapy for chronic pain as soon as possible to long suffering patients is necessary. I am convinced that the medical community at large will know about the efficacy and benefits of this system, but starting with this first clinic, Utahans need not wait for pain relief."
Dr. Chalmers continued, "At the recent American Society of Clinical Oncology, or ASCO, a clinical study was presented on the Calmare systems effectiveness with chronic pain from chemotherapy treatments. The results, again, were very positive. It is a rare opportunity for a physician such as myself to be involved in the introduction of a new medical technology for the treatment of such a challenging medical condition as chronic and intractable pain."
Ms. Kris Hafer, a recent patient of Dr. Chalmers, said, "I have lived with constant pain for the past thirty-two years with a pain score of 7-8 despite three back surgeries and trying epidurals and painkillers that made me nauseous and groggy. I really felt I had exhausted all my options. But after completing the ten 45-minute sessions with this new technology, I have been pain free for more than sixty days and I have discontinued all my pain medications." She added, "I really do not know if I can emphasize enough how thrilling it is to now have a pain score of zero. I have not had zero pain for more than three decades. The change in my daily life has been nothing short of remarkable."
The Calmarereg ; Pain Therapy Treatment medical device technology is a non-invasive medical device for the treatment of high-intensity oncologic and neuropathic pain, including pain resistant to traditional painkillers which often have bad side effects and possible addiction such as morphine and other drugs. Calmarereg ; directs a low electrical current to the patients central nervous system through electrodes placed topically on the patients skin on either side of the pain area. Utilizing proprietary electrical impulse algorithms programmed in the Calmarereg ; system, the technology targets the bodys C-fiber pathway (which transmits slower and chronic pain signals) versus the acute pain pathway. Instead of "blocking" the pain message which is what traditional TENS therapy offers, these electrical signals "re-program" the brain to recognize the pain signal as "normal" and achieve long lasting pain relief. The patented Calmarereg ; technology offers clinicians with a non-invasive and non-narcotic therapy for the relief of chronic pain.
More information about the Calmarereg ; Pain Therapy Treatment is available at www.CalmareTT.com.
About Spero Pain Therapy, Inc. (www.sperotherapy.com)
Spero Pain Relief Therapy, Inc. was founded by Dr. Robert Chalmers to provide innovative solutions to patients suffering from chronic pain.
Contact:
Robert Chalmers, M.D.
Spero Pain Relief Therapy, Inc.
e-mail: rob.chalmerssperotherapy.com
phone (435)656-1916
Eme sajtótájékoztató kapcsolat tartója:
Judith Horsch[Mehr PMs]
[Quelle dieser Pressemitteilung]
[Webslice]
[Mitglieds-RSS] ![]()

[iGoogle]
[Rechtliches] ![]()
Das Copyright von auf premiumpresse.de aufgeführten Bildern und Texten liegt ausschließlich beim Herausgeber/Verfasser der zum Bild/Text zugehörigen Meldung und darf ohne Erlaubnis der in der jeweiligen Meldung genannten Herausgeber/Verfasser/Urheber nicht weiterverarbeitet oder in jeglicher Form verwendet werden. Ausschließlich der Verfasser/Herausgeber der jeweiligen Meldung ist für Art, Beschaffenheit und deren Inhalt sowie beigefügte Texte, Bilder und Tonmaterial verantwortlich. premiumpresse.de kann keinerlei Haftung für Wahrheitsgehalt, Vollständigkeit und/oder Korrektheit veröffentlichter Meldungen übernehmen. In Contentbereichen ggf. grün markierte Textbestandteile (In-Text-Werbungen) stammen nicht vom Urheber der jeweiligen Mitteilung. Orange markierte Verlinkungen mit doppelter blauer Unterstreichung in Contentbereichen stammen entweder vom Verfasser und/oder Publizierenden der jeweiligen Meldung oder werden mittels sogenannter InPress-Links automatisiert zur Thematik eines Wortes ergänzt. User können derart hinterlegte (Werbe)informationen mittels Mouseover selektieren und die Verlinkung(en) ausführen/besuchen. © 2007-2012 premiumpresse.de ist angemeldete Marke beim Deutschen Patent- und Markenamt